Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.42 |
| ▸ | Q9HBH1 | 1/20 | 0.42 | |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9543019 | 0.99 | HDAC3 (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL10380405 | 0.99 | HDAC3 (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL7047405 | 0.92 | SSTR3 (0.49) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL9013073 | 0.92 | SSTR3 (0.49) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL3277643 | 0.91 | SSTR3 (0.48) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL8532855 | 0.90 | KEAP1 (0.42) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL30686001 | 0.88 | MAPK8 (0.45) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| SCHEMBL7761782 | 0.87 | PDF (0.55) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| Edetic Acid SCHEMBL8001970 | 0.86 | SSTR3 (0.44) | HDAC3HDAC11HDAC6HDAC1HDAC2 | |
| Nitrobenzene SCHEMBL29006904 | 0.86 | CTSC (0.41) | HDAC3HDAC11HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113913491-B | Method for measuring protein C activity, reagent for measuring protein C activity, and method for producing the same | 青岛大学附属医院 | 2023-09-29 | — | — | CN | claimed |
| CN-110714051-B | Protein C activity determination kit | 迈克生物股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| JP-59102400-A | — | — | None | — | — | JP | disclosed |
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-3812772-B1 | METHOD FOR DIAGNOSING FIBRINOLYTIC INSUFFICIENCY RELATED TO NEUTROPHIL EXTRACELLULAR TRAPS | HOPITAUX UNIV DE STRASBOURG HUS (FR) | 2025-02-19 | — | — | EP | disclosed |
| CN-114615984-B | Benzoxazinone compounds as dual KLK5/7 inhibitors | 分子皮肤治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240288446-A1 | METHOD FOR DIAGNOSING FIBRINOLYTIC INSUFFICIENCY RELATED TO NEUTROPHIL EXTRACELLULAR TRAPS | HÔPITAUX UNIVERSITAIRES DE STRASBOURG (FR) | 2024-08-29 | — | — | US | disclosed |
| EP-4347641-A1 | PLASMA FRACTIONATION BY CONTINUOUS EXTRACTION | CSL Behring AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| CN-113913491-B | Method for measuring protein C activity, reagent for measuring protein C activity, and method for producing the same | 青岛大学附属医院 | 2023-09-29 | — | — | CN | disclosed |
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| CN-110714051-B | Protein C activity determination kit | 迈克生物股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997049404-A1 | ANTICOAGULANT AGENTS | ELI LILLY AND COMPANY (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| EP-0676964-A1 | NITROSYLATION OF PROTEIN SH GROUPS AND AMINO ACID RESIDUES AS A THERAPEUTIC MODALITY | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-10-18 | — | — | EP | disclosed |
| EP-0676964-A4 | NITROSYLATION OF PROTEIN SH GROUPS AND AMINO ACID RESIDUES AS A THERAPEUTIC MODALITY. | BRIGHAM & WOMENS HOSPITAL (US) | 1995-08-10 | — | — | EP | disclosed |
| WO-1993009806-A1 | NITROSYLATION OF PROTEIN SH GROUPS AND AMINO ACID RESIDUES AS A THERAPEUTIC MODALITY | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1993-05-27 | — | — | WO | disclosed |
| EP-0175729-A1 | MOLECULAR FILM SUPPORTED FROM A FIBRIN NETWORK ENABLING THE SELECTIVE RETENTION, AT ITS SURFACE, OF THE TISSULAR PLASMINOGENE ACTIVATOR AND APPLICATIONS DERIVED THEREFROM | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1986-04-02 | — | — | EP | disclosed |
| WO-1985004425-A1 | MOLECULAR FILM SUPPORTED FROM A FIBRIN NETWORK ENABLING THE SELECTIVE RETENTION, AT ITS SURFACE, OF THE TISSULAR PLASMINOGENE ACTIVATOR AND APPLICATIONS DERIVED THEREFROM | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M (FR) | 1985-10-10 | — | — | WO | disclosed |
| JP-S59102400-A | METHOD FOR MEASURING BIOLOGICAL ACTIVITY OF ANTITHROMBIN III | FUJIMOTO DAIAGUNOSUTEITSUKUSU:KK | 1984-06-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | TFPI, F2, TFPI2 | HDAC3 1017/4885HDAC11 506/4885HDAC6 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.